Phcog.Net logo
Submit

BROWSE ALL JOURNALS

    SEE ALL 6 JOURNALS
    Journal of Pharmacology and PharmacotherapeuticsNOW IN
    Article

    Benfluorex withdrawal in France: Still be hiding somewhere in the world?

    Irène Frachon1, Grégoire Gal1, Catherine Hill1, Christophe Leroyer1★★ Corresponding author

    1. 1Christophe Leroyer Université Européenne de Bretagne, UBO, EA3878 (GETBO) [Downloaded free from http://www.jpharmacol.com on Wednesday, October 13, 2021, IP: 157.45.222.78].

    CORRESPONDENCE

    Christophe Leroyer

    Christophe Leroyer Université Européenne de Bretagne, UBO, EA3878 (GETBO) [Downloaded free from http://www.jpharmacol.com on Wednesday, October 13, 2021, IP: 157.45.222.78].

    christophe.leroyer@chu-brest.fr

    Volume 2, Issue 4 · pp. 307–308 · PUBLISHED 2011 · DOI: 10.4103/0976-500X.85942

    View on J Pharmacol. Pharmacother. original site ↗

    ABSTRACT

    Bhattacharyya et al. have recently reviewed the evidences demonstrating the association between the development of valvular heart disease and the use of appetite suppressants, including fenfl uramine.[1] Among numerous epidemiological data, evidence for a dose-effect relationship as well as demonstration of the underlying mechanism trough involvement of 5HT2B serotonin strongly argue for fenfl uramine exposure as a causal factor for valvular heart disease

    KEYWORDS

    Open in new tab

    REFERENCES

    As published

    Showing references and in-text citations exactly as published.

      Cite this article

      SELECT FORMAT

      Frachon, I., Gal, G., Hill, C., & Leroyer, C. (2011). Benfluorex withdrawal in France: Still be hiding somewhere in the world?. Journal of Pharmacology and Pharmacotherapeutics, 2(4), 307–308. https://doi.org/10.4103/0976-500X.85942